Catalyst
Slingshot members are tracking this event:
Array (ARRY) Expects Results on Sept 9 2017 from Phase 3 BEACON Trial Evaluating Encorafenib/Binimetinib/Cetuximab in BRAF-Mutant Colorectal Cancer
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ARRY |
|
|
||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 08, 2017
Occurred Source:
http://investor.arraybiopharma.com/phoenix.zhtml?c=123810&p=irol-newsArticle&ID=2299508
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Mek+braf+egfr, Beacon Crc, Erbitux, Brafm, Binimetinib
